Texas Permanent School Fund Has $3.48 Million Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Posted by Defense World Staff on May 8th, 2023

Texas Permanent School Fund lessened its position in Exelixis, Inc. (NASDAQ:EXEL – Get Rating) by 6.3% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 216,854 shares of the biotechnology company’s stock after selling 14,600 shares during the period. Texas Permanent School Fund owned approximately 0.07% of Exelixis worth $3,478,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Signaturefd LLC grew its stake in Exelixis by 28.8% in the fourth quarter. Signaturefd LLC now owns 2,767 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 619 shares during the period. CWM LLC boosted its position in shares of Exelixis by 12.8% during the third quarter. CWM LLC now owns 6,053 shares of the biotechnology company’s stock valued at $95,000 after buying an additional 687 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund boosted its position in shares of Exelixis by 5.6% during the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 13,253 shares of the biotechnology company’s stock valued at $208,000 after buying an additional 703 shares during the last quarter. US Bancorp DE boosted its position in shares of Exelixis by 1.1% during the third quarter. US Bancorp DE now owns 75,522 shares of the biotechnology company’s stock valued at $1,184,000 after buying an additional 786 shares during the last quarter. Finally, Louisiana State Employees Retirement System boosted its position in shares of Exelixis by 0.9% during the fourth quarter. Louisiana State Employees Retirement System now owns 86,400 shares of the biotechnology company’s stock valued at $1,386,000 after buying an additional 800 shares during the last quarter. Institutional investors and hedge funds own 84.74% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on EXEL. JMP Securities cut their target price on Exelixis from $25.00 to $24.00 and set a “market outperform” rating on the stock in a research report on Thursday, January 19th. Piper Sandler reissued an “overweight” rating and issued a $32.00 price objective on shares of Exelixis in a research report on Wednesday, February 8th. Credit Suisse Group assumed coverage on Exelixis in a research report on Thursday, January 26th. They issued an “outperform” rating and a $29.00 price objective on the stock. Morgan Stanley cut their price objective on Exelixis from $22.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 12th. Finally, Wells Fargo & Company assumed coverage on Exelixis in a research report on Thursday, March 9th. They issued an “overweight” rating and a $23.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Exelixis presently has a consensus rating of “Moderate Buy” and an average price target of $25.92.

Insider Transactions at Exelixis

In other news, Director Jack L. Wyszomierski sold 15,300 shares of the firm’s stock in a transaction that occurred on Friday, March 10th. The shares were sold at an average price of $16.61, for a total value of $254,133.00. Following the transaction, the director now owns 317,467 shares in the company, valued at $5,273,126.87. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Alan M. Garber sold 40,000 shares of Exelixis stock in a transaction dated Tuesday, February 21st. The stock was sold at an average price of $17.49, for a total value of $699,600.00. Following the completion of the transaction, the director now owns 31,417 shares of the company’s stock, valued at approximately $549,483.33. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Jack L. Wyszomierski sold 15,300 shares of Exelixis stock in a transaction dated Friday, March 10th. The stock was sold at an average price of $16.61, for a total value of $254,133.00. Following the completion of the transaction, the director now directly owns 317,467 shares of the company’s stock, valued at approximately $5,273,126.87. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 212,100 shares of company stock worth $3,777,839. Insiders own 2.90% of the company’s stock.

Exelixis Stock Performance

Shares of Exelixis stock opened at $19.48 on Monday. Exelixis, Inc. has a 52-week low of $14.87 and a 52-week high of $22.47. The stock has a market capitalization of $6.33 billion, a price-to-earnings ratio of 34.18, a P/E/G ratio of 0.78 and a beta of 0.68. The company’s 50 day moving average price is $18.52 and its 200-day moving average price is $17.38.

Exelixis (NASDAQ:EXEL – Get Rating) last issued its earnings results on Tuesday, February 7th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.04). Exelixis had a return on equity of 7.54% and a net margin of 11.31%. The firm had revenue of $423.92 million during the quarter, compared to the consensus estimate of $418.71 million. During the same quarter in the prior year, the business posted $0.29 EPS. The firm’s revenue for the quarter was down 6.0% on a year-over-year basis. As a group, equities research analysts forecast that Exelixis, Inc. will post 0.69 earnings per share for the current fiscal year.

Exelixis Company Profile

(Get Rating)

Exelixis, Inc operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Texas Permanent School Fund Has $3.48 Million Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Analysts Set New Price Targets

Insider Transactions at Exelixis

Exelixis Stock Performance

Exelixis Company Profile

Further Reading

You might be interested in: